Platinum-based chemotherapy has been the standard first-line treatment for patients with advanced non-small-cell lung cancer for decades. However, a recent study has shown the superiority of gefitinib treatment in comparison with chemotherapy in a molecularly selected cohort of patients harboring sensitizing EGFR mutations. These results demonstrate the importance of incorporating molecular selection into the design of lung cancer trials that use EGFR tyrosine kinase inhibitors.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma
Oncogenesis Open Access 14 March 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069–1075 (2008).
Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121–128 (2010).
Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005).
Kim, E. S. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372, 1809–1818 (2008).
Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
Giaccone, G. et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study. Clin. Cancer Res. 12, 6049–6055 (2006).
Jackman, D. M. et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin. Cancer Res. 15, 5267–5273 (2009).
Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Kobayashi, K. et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: A phase III study (002) by North East Japan Gefitinib Study Group [abstract]. J. Clin. Oncol. 27 (Suppl.), 8016 (2009).
Schiller, J. H. et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 346, 92–98 (2002).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lopez-Chavez, A., Giaccone, G. Importance of patient selection for EGFR TKIs in lung cancer. Nat Rev Clin Oncol 7, 360–362 (2010). https://doi.org/10.1038/nrclinonc.2010.72
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.72
This article is cited by
-
PEST-containing nuclear protein regulates cell proliferation, migration, and invasion in lung adenocarcinoma
Oncogenesis (2019)
-
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Nature Reviews Clinical Oncology (2011)
